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MaBACKGROUND Hypertrophic cardiomyopathy (HCM) has been prominently associated with adverse disease compli-
cations, including sudden death or heart failure death and a generally adverse prognosis, with annual mortality rates of
up to 6%.
OBJECTIVES This study determined whether recent advances in management strategy, including implantable
cardioverter-deﬁbrillators (ICDs), heart transplantation, or other therapeutic measures have signiﬁcantly improved
survival and the clinical course of adult HCM patients.
METHODS We addressed long-term outcomes in 1,000 consecutive adult HCM patients presenting at 30 to 59 years of
age (mean 45  8 years) over 7.2  5.2 years of follow-up.
RESULTS Of 1,000 patients, 918 (92%) survived to 53  9.2 years of age (range 32 to 80 years) with 91% experiencing
no or only mild symptoms at last evaluation. HCM-related death occurred in 40 patients (4% [0.53%/year]) at 50  10
years from the following events: progressive heart failure (n ¼ 17); arrhythmic sudden death (SD) (n ¼ 17); and embolic
stroke (n ¼ 2). In contrast, 56 other high-risk patients (5.6%) survived life-threatening events, most commonly with ICD
interventions for ventricular tachyarrhythmias (n ¼ 33) or heart transplantation for advanced heart failure (n ¼ 18
[0.79%/year]). SD occurred in patients who declined ICD recommendations, had evaluations before application of pro-
phylactic ICDs to HCM, or were without conventional risk factors. The 5- and 10-year survival rates (conﬁned to HCM
deaths) were 98% and 94%, respectively, not different from the expected all-cause mortality in the general U.S. pop-
ulation (p ¼ 0.25). Multivariate independent predictors of adverse outcome were younger age at diagnosis, female sex,
and increased left atrial dimension.
CONCLUSIONS In a large longitudinally assessed adult HCM cohort, we have demonstrated that contemporary man-
agement strategies and treatment interventions, including ICDs for SD prevention, have signiﬁcantly altered the clinical
course, now resulting in a low disease-related mortality rate of 0.5%/year and an opportunity for extended
longevity. (J Am Coll Cardiol 2015;65:1915–28) © 2015 by the American College of Cardiology Foundation.m the *Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota; and the
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ABBR EV I A T I ON S
AND ACRONYMS
CMR = cardiovascular
magnetic resonance
HCM = hypertrophic
cardiomyopathy
ICD = implantable
cardioverter-deﬁbrillator
LGE = late gadolinium
enhancement
LV = left ventricular
NYHA = New York
Heart Association
SD = sudden death
VF = ventricular ﬁbrillation
VT = ventricular
tachyarrhythmia
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1916H ypertrophic cardiomyopathy (HCM)has been historically associatedwith substantial morbidity and mor-
tality and impaired longevity due to sudden
death (SD) and complications of heart failure
(1–10). However, the previous 15 years have
witnessed the emergence of innovative non-
pharmacological cardiovascular management
strategies for HCM patients, including an
expanded risk stratiﬁcation algorithm, use of
implantable cardioverter-deﬁbrillators (ICDs)
for SD prevention, and advances in refractory
heart failure therapies, including heart trans-
plantation (11–19).SEE PAGE 1929Nevertheless, there is limited objective
evidence available supporting a cardiovascular mor-
tality beneﬁt attributable to contemporary manage-
ment options within established HCM cohorts, and
some uncertainty may persist in the practicing
community (10,20). Generally, in adult cardiovascular
practice, patients between 30 and 59 years of age
(midlife) with HCM constitute the subgroup most
commonly presenting for clinical evaluation and are
frequently subject to adverse complications. There-
fore, we have taken this opportunity to assemble
longitudinal cohort data in 1,000 adult patients pre-
senting in this midlife age group to determine the
extent to which therapeutic interventions have
altered clinical course.
METHODS
PATIENT SELECTION. Databases from 2 HCM cen-
ters, Minneapolis Heart Institute and Tufts Medical
Center, identiﬁed 1,001 consecutive HCM patients
presenting to those institutions at 30 to 59 years of
age between 1992 and 2011, inclusive. Patients were
referred and enrolled for targeted subspecialty eval-
uation, risk stratiﬁcation and treatment, or to estab-
lish the diagnosis of HCM.
Recent vital clinical status up to December 2013
was obtained by hospital visit or systematic tele-
phone contact (or by social security death index) in
1,000 patients (19). One patient was lost to follow-up
due to residence outside of the United States. Com-
plete and detailed clinical records at follow-up could
be obtained in 979 of 1,000 patients (98%).
Follow-up duration from study entry (at ﬁrst visit)
to most recent contact or death was 7.2  5.2 years
(ranging to 37 years). Diagnosis of HCMwas on the basis
of echocardiographic and/or cardiovascular magnetic
resonance (CMR) demonstration of a hypertrophiedand nondilated left ventricle (LV) with wall thickness
$13 mm, in the absence of other cardiac or systemic
diseases capable of producing a similar magnitude of
hypertrophy (1,2,5,6,21). Deaths due to heart failure or
SD were deﬁned as previously reported (9). Patients
with known HCM phenocopies (e.g., Fabry disease,
lysosomal associated membrane protein-2 (LAMP2)
cardiomyopathy, or amyloidosis) were excluded. This
study was reviewed and approved by Institutional
Review Boards of the participating institutions Allina
Health System and Tufts Medical Center, permitting
use of patient medical information for research. All
authors had full access to data and take responsibility
for the integrity of the data and agreed to the paper as
written.
IMAGING. Transthoracic echocardiographic studies
were performed in standard fashion. LV wall thick-
ness was the maximal end-diastolic dimension within
the chamber (usually the ventricular septum).
Continuous-wave Doppler was used to estimate the
peak instantaneous LV outﬂow gradient. Obstruction
was deﬁned as a gradient $30 mm Hg, and the non-
obstructive state as <30 mm Hg at rest and with ex-
ercise (20,22,23).
CMR studies were performed in 465 patients with a
1.5-T clinical scanner. Cine sequences were per-
formed in standard views with full LV coverage. Late
gadolinium enhancement (LGE) images were ac-
quired 10 to 15 min after intravenous administration
of 0.2 mmol/kg gadolinium-diethylene triamine
pentaacetic acid, using a breath-held segmented
inversion-recovery sequence. LGE quantiﬁcation was
performed by manually adjusting the gray scale
threshold to visually deﬁne LGEs, which were sum-
med and expressed as a proportion of the total LV
myocardium (24).
DEFIBRILLATORS. Single- or dual-chamber ICDs
capable of antitachycardia and antibradycardia pac-
ing were implanted in 389 patients for primary
(n ¼ 383) or secondary (n ¼ 6) prevention, according
to the risk stratiﬁcation model advanced for HCM in
guidelines and consensus panels (1–6). Major con-
ventional risk factors (1–3,5–8) are: 1) family history of
SD due to HCM; 2) unexplained recent syncope;
3) multiple repetitive nonsustained ventricular
tachycardia on ambulatory electrocardiography (ECG)
monitoring; 4) hypotensive or blunted blood pressure
response to exercise; 5) massive LV hypertrophy (wall
thickness $30 mm).
Expert electrophysiologists at each center analyzed
stored intracardiac electrocardiograms for arrhyth-
mias responsible for deﬁbrillator discharges (shocks or
antitachycardia pacing), according to prior deﬁnitions
TABLE 1 Demographics, Clinical Features, and Outcome in
1,000 HCM Patients Presenting at 30 to 59 Years of Age
Age at study entry, yrs 45.7  8.5
30–39 290 (29)
40–49 361 (36)
50–59 349 (35)
Age at last evaluation, contact, or death, yrs 53.2  9.2 (32–80)
30–39 90 (9)
40–49 297 (30)
50–59 369 (37)
60–69 211 (21)
70–79 33 (3)
Males 704 (70)
Age at diagnosis, yrs 40.4  11.3 (0.1–59)
Family history of HCM 361
Family history of HCM death 238
LVOT gradient, $30 mm Hg at rest 272 (27)
LVOT gradient, <30 mm Hg at rest/
$30 mm Hg with exercise
206
Mitral valve systolic anterior motion 655
Left atrial dimension, mm 42.3  7.2 mm (20–79)
LVED transverse dimension, mm 43.9  6.8 (21–97)
Maximal LV thickness, mm 21.7  5.5 (13–48)
Atrial ﬁbrillation 265 (27)
Myectomies 226*
Post-operative myectomy deaths 2 (0.8)
Alcohol septal ablations 27
Heart transplantations 25
ICDs 389†
LV apical aneurysms/
regional scarring
32
All 5 major conventional risk markers 687 (69)‡
Conventional risk factors
0 381
1 365
2 189
$3 65
Coronary artery disease 71§
NYHA-FC initial evaluation
(1,000 patients)
1 526 (52)
2 275 (28)
3–4 199 (20)
NYHA-FC last evaluation (patients)
1 624 (64)
2 263 (27)
3–4 92 (9)
Continued in the next column
Drug therapy at study entry
Beta-blockers 564
Calcium antagonists 272
Diuretic agents 113
Disopyramide 30
ACE/ARB 105
Warfarin 71
Amiodarone 18
Others (sotalol, ﬂecainide, digitalis) 18
Contrast CMR
Patients studied 465
Patients with LGE 200
Patients with LGE $15% of LV 23
% of LGE (n ¼ 200) 6.1  7.7
% of LGE in survivors (n ¼ 175) 5.6  7.4k
% of LGE (SD/ICD terminated) (n ¼ 12) 6.6  6.9
% of LGE (severe heart failure/
death/transplant) (n ¼ 9)
8.7  9.4
Nonfatal embolic stroke 22 (2.2)
Fatal embolic stroke 2 (0.2)
Sarcomere mutations
Myosin-binding protein C 40
b-myosin heavy chain 23
Troponin T 6
Troponin I 1
Troponin C 1
a-tropomyosin 3
Myosin-binding protein C and
b-myosin heavy chain
1
Myosin-binding protein C and troponin I 2
Values are mean  SD, n (%), mean  SD (interquartile range), or n. *Does not
include 5 patients who also underwent alcohol septal ablation; of 258 septal
reduction procedures, 217 were performed after the ﬁrst visit and study entry.
†Includes 82 patients who received ICDs before the ﬁrst visit to the participating
center; of the 383 patients who received implants for primary prevention, 341
had $1 conventional risk marker, and among the other 42, indications were end-
stage heart failure (n ¼ 19), LV apical aneurysm (n ¼ 12), extensive LGE (n ¼ 3),
or complete heart block after alcohol septal ablation (n ¼ 8). ‡Hypotensive/
attenuated blood pressure response to exercise was not tested in 279 patients, but
ancillary risk markers were identiﬁed in 48 other patients: LV apical aneurysm,
end-stage progression, or extensive LGE. §Includes 53 patients requiring inter-
vention (stents, bypass surgery, or percutaneous coronary procedure); 488 pa-
tients were imaged with coronary arteriography or CT angiography. kLGE in
survivors vs. SD/ICD terminated, or vs. severe heart failure or death or transplant;
p values 0.21 to 0.65.
ACE/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin II receptor
blockers; BP ¼ blood pressure; C ¼ chronic; CMR ¼ cardiovascular magnetic
resonance; HCM ¼ hypertrophic cardiomyopathy; ICD ¼ implantable cardioverter-
deﬁbrillator; LGE ¼ late gadolinium enhancement; LV ¼ left ventricular; LVED ¼
left ventricular end-diastolic dimension; LVH ¼ left ventricular hypertrophy;
LVOT ¼ left ventricular outﬂow tract; NSVT ¼ nonsustained ventricular tachy-
cardia; NYHA-FC ¼ New York Heart Association functional class; P ¼ paroxysmal;
SD ¼ sudden death.
TABLE 1 Continued
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1917in HCM studies (12). Device deﬁbrillator discharges
were considered appropriate when triggered by ven-
tricular ﬁbrillation or rapid sustained ventricular
tachycardia (rate: >180/min). Rate cutoffs for
arrhythmia detection were programmed and anti-
tachycardia pacing activated at the electrophysiolo-
gist’s discretion.
Other major interventions included septal reduc-
tion therapy (226 underwent septal myectomy; 27 had
alcohol septal ablation), and 25 others underwentheart transplantation. All major HCM-related events,
including out-of-hospital cardiac arrest, occurred af-
ter the initial visit to a participating institution.
STATISTICAL ANALYSES. Descr ipt ive stat i s t i cs .
Data are mean  SD for continuous variables and
proportions for categorical variables; where contin-
uous variables had skewed distributions, data are
expressed as median (25th, 75th percentiles). Student
t-test or Wilcoxon rank-sum tests assessed the
TABLE 2 Patients With HCM-Related Deaths or Major Events and Interventions
Patient #
Age at Initial
Evaluation
(yrs) Sex
Age at Death
or Event
(yrs)
NYHA LVOTG
(at Rest)
(mm Hg)
Max LV
Thickness
(mm) AF
LA
(mm) % of EF CommentsInitial Last
HCM-related deaths
Sudden cardiac death
1 31.1 M 37.9 1 3 58 31 0 50 75 Declined ICD; NSVT; LV $30 mm
2 32.6 M 36.4 1 1 0 30 0 33 80 Declined ICD; syncope; LVH $30 mm
3 33.4 M 41.6 1 1 25 37 0 43 70 Declined ICD; family history of SD; NSVT; LV $30 mm
4 33.8 M 36.2 2 1 17 32 0 43 65 Pre-ICD era; LV $30 mm; myectomy 17 yrs prior
5 34.2 M 41.8 2 2 0 20 0 42 70 Pre-ICD era without risk factors
6 34.3 M 41.0 2 2 0 18 0 36 65 ICD failed
7 38.1 F 39.7 1 1 0 18 0 50 65 LV apical aneurysm
8 43.1 M 44.0 1 1 35 24 0 44 60 Pre-ICD era without risk factors
9 43.8 M 45.0 2 2 75 20 0 46 65 Without risk factors
10 45.6 M 52.4 2 2 0 19 C 76 60 Declined ICD; family history of SD; myectomy 15 yrs prior
11 46.0 F 50.6 1 2 30 25 0 42 65 Pre-ICD era; family history of SD; syncope; LV $30 mm
12 46.8 M 47.5 1 1 0 22 0 48 70 Pre-ICD era; NSVT
13 49.6 M 55.3 2 2 0 20 P 49 60 Without risk factors
14 52.9 M 58.3 2 2 0 15 0 38 65 Declined ICD; syncope; NSVT
15 53.8 M 55.6 1 1 35 17 0 48 65 Pre-ICD era without risk factors
16 56.8 M 59.1 1 1 0 19 0 41 65 Declined ICD; family history of SD; NSVT
17 58.6 M 61.4 2 2 0 23 0 46 80 Without risk factors
Advanced (end-stage) heart failure without transplant
1 32.9 M 42.1 2 3 0 20 0 54 15 HF death 12 y post-operative myectomy
2 38.4 M 52.6 1 3 0 18 0 33 25 Declined transplant
3 39.0 M 44.6 2 3 0 17 0 52 65 Died awaiting transplant
4 39.1 M 45.5 3 3 0 18 0 33 20 Denied transplant (comorbidities)
5 39.2 M 42.0 3 3 0 22 C 79 23 Died of HF awaiting transplant; myectomy 21 yrs prior
6 42.5 F 47.9 1 3 0 17 P 33 40 Died of HF awaiting transplant; family history of end-stage HF
7 45.5 F 68.9 3 3 0 20 C 68 35 HF death 17 yrs post successful myectomy; family history of
end-stage HF
8 47.8 M 67.8 2 3 0 20 0 43 60 Declined transplant; family history of end-stage HF
9 54.4 F 57.5 3 3 0 30 0 50 60 Denied transplant due to comorbidities; died 14 yrs
post-myectomy
10 56.1 F 70.1 1 3 0 19 0 49 49 Declined transplant
11 57.7 F 66.1 1 3 0 28 C 55 40 Denied transplant (comorbidities)
Advanced (end-stage) heart failure without transplant and prior ICD intervention
1 56.6 F 59.9 3 4 110 23 P 54 65 Died of HF awaiting transplant; 4 y post-myectomy; ICD shock
20 months prior to death
Post-operative
1 44.0 M 44.3 3 3 100 25 C 48 30 Aneurysm resection and myectomy
2 44.3 M 45.6 2 3 81 17 0 46 70 Myectomy complicated by VSD
3 48.5 F 48.5 4 4 100 30 0 40 70 Myectomy and MVR
4 51.8 F 58.0 3 4 115 25 C 43 60 MVR and CABG; ASA 6.2 yrs prior
Embolic stroke
1 36.2 M 42.1 2 2 135 19 P 43 70 In AF on warfarin; myectomy 3.7 yrs prior
2 52.8 M 61.1 2 2 36 40 P 48 65 History of AF; noncompliant with warfarin
Post-transplant deaths
1 41.7 M 47.1 4 2 0 12 C 60 10 Died of lymphoma 18 yrs post-transplant; family history
end-stage HF
2 43.7 M 46.9 3 3 0 20 0 36 45 2 heart transplants 12 yrs apart; also kidney transplant;
died 2 yrs after last transplant
3 46.8 M 49.7 2 3 0 30 P 60 25 Died of Hodgkin’s disease 10 yrs post-transplant
4 52.1 F 57.8 1 4 0 11 0 35 50 Died RV failure 3 days post-operative; myectomy 32.6 yrs prior
Transplant complication and prior ICD intervention
1 45.2 F 46.4 2 2 0 14 P 60 30 ICD intervention 1.5 yrs prior to transplant; died 6 yrs
post-transplant after cardiac arrest; family history of
end-stage HF
Continued on the next page
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TABLE 2 Continued
Patient #
Age at Initial
Evaluation
(yrs) Sex
Age at Death
or Event
(yrs)
NYHA LVOTG
(at Rest)
(mm Hg)
Max LV
Thickness
(mm) AF
LA
(mm) % of EF CommentsInitial Last
Nonfatal HCM-related major events
Resuscitated cardiac arrest
1 30.7 M 37.4 1 1 0 25 P 39 70 Without risk factors
2 37.0 M 37.8 2 2 23 23 0 49 65 Family history of SD
3 50.6 M 53.0 1 1 0 17 P 37 70 Declined ICD; history of NSVT
Resuscitated cardiac arrest and ICD intervention after
1 35.3 F 37.8 1 1 31 20 0 36 65 NSVT; ICD shock 6 months after
2 43.0 M 57.9 2 2 65 20 0 43 60 History of NSVT; CAD involving the RCA and ﬁrst diagonal;
currently in end-stage HF
Appropriate ICD interventions
1 32.3 M 42.8 2 3 0 31 0 45 70 NSVT; LV $30 mm
2 32.6 M 37.8 1 1 0 18 0 38 65 LV apical aneurysm
3 33.0 M 36.0 2 1 75 44 0 44 70 Family history of SD; syncope; LV $30 mm
4 33.3 F 35.0 1 1 80 25 0 43 65 Family history of SD; abnormal BP response
5 33.7 F 39.0 1 1 0 16 0 28 65 Syncope; abnormal BP response
6 35.4 M 41.4 1 1 0 31 0 36 65 Family history of SD; syncope; NSVT; LV $30 mm
7 36.8 F 39.4 3 3 0 22 P 38 75 Family history of SD; abnormal BP response
8 36.9 M 37.4 1 1 65 21 P 42 60 Family history of SD
9 37.0 F 44.1 1 1 0 17 P 33 50 NSVT
10 38.1 M 65.3 1 2 0 31 P 49 60 NSVT; LV $30 mm
11 40.0 F 41.8 2 2 90 29 P 68 55 NSVT
12 41.4 F 42.8 1 1 0 22 0 52 55 Family history of SD; NSVT
13 42.2 M 43.4 1 1 0 23 0 30 60 NSVT
14 42.8 M 48.8 2 1 0 35 P 56 70 Syncope; LV $30 mm; abnormal BP response
15 42.8 M 62.9 3 2 40 25 C 48 60 Syncope; NSVT
16 44.3 F 52.3 1 1 0 25 0 35 65 Family history of SD
17 44.3 M 48.9 1 1 30 28 0 27 52 Syncope; NSVT; LV apical aneurysm
18 44.5 F 47.1 2 2 0 28 0 24 73 NSVT; LV $30 mm
19 44.6 F 48.6 3 3 0 15 C 53 55 End-stage HF; myectomy 12 yrs prior; declined transplant
20 44.9 F 46.2 1 1 20 21 0 38 70 Family history of SD; syncope
21 47.0 M 56.2 2 2 160 23 C 45 70 NSVT
22 48.5 F 49.9 1 1 74 18 0 50 70 Family history of SD; NSVT
23 48.6 F 49.0 3 2 0 18 0 47 60 Family history of SD; syncope
24 51.5 M 56.8 3 2 74 15 C 52 65 Family history of SD
25 51.7 M 61.6 1 1 0 28 0 42 60 Syncope; NSVT
26 53.6 M 58.3 1 1 0 30 0 36 55 LV $30 mm
27 53.8 F 62.1 3 3 0 21 0 45 60 Family history of SD; NSVT; LV apical aneurysm; ASA 11 yrs
prior to ICD intervention; now listed for transplant
28 55.1 F 59.4 3 3 0 23 P 45 70 Family history of SD; syncope
29 57.4 M 63.4 1 1 0 19 P 40 60 Without risk factors
30 58.6 F 65.8 3 3 0 18 P 32 65 Family history of SD; syncope
31 59.6 M 68.7 3 2 65 40 P 52 80 Syncope; LV $30 mm
ICD interventions-appropriate and heart transplantation thereafter
1 34.5 M 39.3 1 1 0 17 P 50 55 Syncope; NSVT; transplant 12 months after ICD intervention
2 40.6 F 43.3 3 1 0 17 P 45 50 Family history of SD; NSVT; transplant 14 months after ICD
intervention
Continued on the next page
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1919statistical signiﬁcance of continuous variables, and
chi-square or Fisher exact test analyzed categorical
variables.
Clinical parameters were tested as univariate pre-
dictors of HCM-related mortality or life-threatening
events (n ¼ 96). A p value of <0.05 was considered sig-
niﬁcant and was presented as 2-sided where appropriate.
Variables with a p value of <0.05 for univariateassociations were entered into a stepwise multivariate
Cox proportional hazards model to identify independent
predictors. Proportional hazards assumptionswere tested
graphically before proceeding. Statistical calculations
were carried out using Stata version 11.2 software (Stata-
Corp; College Station, Texas).
Surv iva l and event analys i s . For patients with
known survival and event status, the fraction at each
TABLE 2 Continued
Patient #
Age at Initial
Evaluation
(yrs) Sex
Age at Death
or Event
(yrs)
NYHA LVOTG
(at Rest)
(mm Hg)
Max LV
Thickness
(mm) AF
LA
(mm) % of EF CommentsInitial Last
Heart transplantation
1 30.5 F 32.1 3 1 0 15 P 48 30
2 32.1 M 39.2 3 1 0 30 C 55 40 Successful myectomy 7 yrs prior
3 32.5 M 50.4 1 1 0 33 0 51 69 18 yrs prior to transplant LVOTG 86 mm Hg
4 34.0 F 41.2 2 2 0 25 C 54 57 Family history of end-stage HF
5 36.7 F 45.1 3 1 0 15 0 40 45 Family history of end-stage HF
6 37.3 M 38.8 4 1 0 28 P 60 50 Successful myectomy 23 yrs prior; LVAD prior to transplant
7 39.4 M 45.9 1 1 0 15 0 46 34
8 40.1 F 44.8 3 1 0 10 C 47 40 Family history of end-stage HF; LV remodeling
9 41.2 F 41.7 3 1 0 16 P 52 50
10 41.4 M 47.6 3 1 0 18 C 46 15 LVAD prior to transplant
11 44.9 F 55.2 3 1 0 19 0 44 60
12 46.3 F 49.6 2 1 0 18 P 54 30 Family history of end-stage HF
13 48.0 M 48.9 3 1 0 17 P 53 55
14 49.4 F 58.0 1 1 0 16 P 47 55
15 53.2 M 55.9 2 1 0 22 P 55 50
16 54.0 M 65.7 1 1 0 16 P 55 55 LVAD prior to transplant
17 59.4 M 62.5 3 1 36 21 P 44 45 ASA 3 yrs prior; stent to LAD
18 59.6 F 61.5 3 1 0 12 C 62 49 LV remodeling
AF ¼ atrial ﬁbrillation; ASA ¼ alcohol septal ablation; BP ¼ blood pressure; C ¼ chronic (AF); CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; HF ¼ heart failure; ICD ¼ implantable
cardioverter-deﬁbrillator; LAD ¼ left anterior descending; LV ¼ left ventricular; LVAD ¼ left ventricular assist device; LVH ¼ left ventricular hypertrophy; LVOTG ¼ left ventricular outﬂow tract gradient;
MVR ¼ mitral valve replacement; NSVT ¼ nonsustained ventricular tachycardia on 24-hour ambulatory (Holter) electrocardiography; P ¼ paroxysmal (AF); RCA ¼ right coronary artery; SD ¼ sudden death;
VSD ¼ ventricular septal defect; other abbreviations as in Table 1.
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1920follow-up interval was estimated by the Kaplan-Meier
method. The expected fraction surviving at each time
after the initial visit was computed by assigning a
probability of survival appropriate to age and sex, on
the basis of the U.S. general population (25). Actual
and expected survival fractions were compared using
1-sample log-rank tests, which also provided an esti-
mate for the standardized mortality ratio (SMR) and
95% conﬁdence interval (CI) (26). Computations were
carried out using R version 2.36-14 software (Devel-
opment Core Team 2012, R Project).
RESULTS
PATIENT DEMOGRAPHICS AND SYMPTOMS. Patients
were 45  8 years of age at study entry, 53  9 years at
the most recent evaluation (or death), and 40  11
years of age at HCM diagnosis. Duration of follow-up
was 7.2  5.2 years. Maximal LV wall thickness was 22
 5 mm; $30 mm in 104 (10%) (Tables 1 and 2). At the
initial evaluation, most patients (801 [80%]) were
asymptomatic or mildly symptomatic and demon-
strated New York Heart Association (NYHA) func-
tional classes I and II. At the last evaluation, 91% were
in NYHA functional classes I and II (Table 1).
MORTALITY. Of the 1,000 study patients, 918 (92%)
survived over the follow-up period; 82 (8%) died
(Figures 1 and 2, Table 2).HCM-re lated events . In 40 patients (4% [0.53%/
year]), the cause of deathwas attributable to HCM at 50
 9 years of age (range 36 to 70 years of age) (Central
Illustration). Seventeen deaths were related directly
to advanced heart failure in the absence of LV outﬂow
obstruction (ejection fraction: <50% in 13 patients).
These patients had conditions that were refractory
to vigorous pharmacologic treatment strategies, in-
cluding angiotensin-converting enzyme inhibitors
(n ¼17), diuretic agents (n ¼ 17), beta-blockers (n ¼ 16),
and verapamil (n ¼ 5). Twelve of the 17 patients
who died had either declined heart transplantation,
were ineligible, or were waitlisted; 5 others died of
transplantation-related complications (with 4 of these
surviving 6 to 18 years). Two patients died of embolic
stroke (0.2%) and 4 after HCM-related surgery, for
example, myectomy in 3 and apical aneurysm resec-
tion in 1 (27) (Table 2).
Seventeen patients died suddenly of HCM
(Figure 2, Table 2). Six of these deaths occurred 5  2
years after they had declined a formal recommenda-
tion for prophylactic ICD therapy, at 47  8 years of
age (1–7,12). Eleven additional patients did not
receive ICDs, either because they were judged to be at
low risk without markers (7,28,29) or died in the
1990s, prior to systematic use of ICDs for HCM (15).
None of the 40 HCM patients who died had obstruc-
tive coronary artery disease on the basis of
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1921angiography, angina, myocardial infarction, or acute
coronary event.
Non-HCM events . Forty-two patients (4.2%) died of
causes unrelated to HCM (0.56%/year), including 18 of
noncardiac diseases, most commonly cancer (n ¼ 9)
at 57  10.1 years. In 11 of these patients, demise was
due to multiple, largely noncardiac organ system ab-
normalities and comorbidities unlikely to be linked to
HCM.
Major nonfata l HCM-re lated events . Fifty-six
patients (5.6%) had nonfatal HCM-related events at
0.79%/year (Figure 1, Table 2).
ICD intervent ions . Of the 389 patients with
ICDs, 37 experienced $1 appropriate ICD intervention
for ventricular tachycardia (VT)/ventricular ﬁbrilla-
tion (VF); (5-year cumulative probability: 8.1%),FIGURE 1 Natural History of HCM in Midlife Adults
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1922Five additional patients were resuscitated after
out-of-hospital cardiac arrest, aided by timely thera-
peutic hypothermia in 3 cases (30). All survived to the
end of follow-up at 5.1  3.3 years, 2 with a secondary
prevention ICD shock.
Advanced heart fa i lure and transplant . Twenty
of 25 patients (80%) with nonobstructive HCM un-
dergoing heart transplantation (at 48  7 years) for
unrelenting drug-refractory heart failure symptoms
(ejection fraction: <50% in 17) have survived 4 
4 years (to 17) postoperatively, at 51  9 years
(Central Illustration).
Of the 258 patients who underwent surgical septal
myectomy (31), alcohol ablation (32), or both, to
relieve obstruction and severe heart failure symp-
toms, 232 (90%) are alive at age 53  8 years, of whom
207 are improved in NYHA functional classes I and II.
Myectomy or alcohol ablation patients progressed to
heart transplantation at a rate similar to that in other
patients (4.4%/year vs. 4.7%/year; log-rank p ¼ 0.61).
Eleven other patients were potential candidates
for septal reduction with large outﬂow gradients
(>50 mm Hg) and NYHA functional classes III and IV
symptoms, but 8 refused this therapy and 3 were
ineligible due to comorbidities. Over a follow-up
period of 5.8  3 years, 9 of these patients survived.
EVENT RATES. Aborted HCM mortality, that is,
nonfatal sudden events/interventions, including
appropriate ICD interventions, heart transplantation,and resuscitated out-of-hospital cardiac arrest oc-
curred in 56 patients, 0.79%/year, which is 50%
higher than the HCM mortality rate (Figures 1 and 2).
Multivariate independent predictors of HCM mortal-
ity and life-threatening events (n ¼ 96) were younger
at diagnosis, had increased left atrial dimension, and
female sex (Table 3).
The HCM-related morality rate was 0.53%/year
(Central Illustration). Considering only HCM-related
deaths, survival rates at 5 and 10 years were 98%
(95% CI: 96% to 98%) and 94% (95% CI: 91% to 95%),
respectively, and notably, no different than that
expected for all-cause mortality in an age- and sex-
matched general U.S. population (SMR: 0.83; 95% CI:
0.61 to 1.14; log-rank p ¼ 0.25) (Figure 3B). The com-
bination of HCM-related deaths and life-threatening
events aborted by contemporary treatments signiﬁ-
cantly exceeded all-cause mortality in the general
population (SMR: 2.11; 95% CI: 1.73 to 2.58; log-rank
p < 0.001) (Figure 3C).
All-cause mortality in HCM patients (n ¼ 82; 8.2%)
was 1.16%/year, exceeding that expected in a general
age and sex-matched U.S. population (SMR: 1.68; 95%
CI: 1.35 to 2.08; log-rank p < 0.001) (Figure 3A). Sur-
vival rates at 5 and 10 years were 97% (95% CI: 95% to
97%) and 88% (95% CI: 84% to 90%), respectively.
DISCUSSION
Over the last 15 years, comprehensive HCM-related
management strategies have evolved considerably,
including an expanded risk stratiﬁcation algorithm
with greater appreciation for at-risk patients, leading
to more reliable identiﬁcation of those likely to
achieve SD prevention with ICDs (10–16) and in
accordance with U.S. guidelines (5,6), HCM patients
have also beneﬁted from relief of heart failure
symptoms and extended longevity due to advances
in surgical septal myectomy technique (or alcohol
ablation) and heart transplantation (1–6,10–18,31,32).
Although the effectiveness of such treatments has
been reported in selected high-risk subsets (12–15),
ascertaining their true efﬁcacy on clinical course,
potential mortality, and longevity requires system-
atic assessment in established and consecutively
assembled large adult HCM patient populations
(such as the present one).
We recently recognized patient age as important
in the natural history and clinical course of HCM,
and decisions governing major treatment inter-
ventions (19,33), by demonstrating that advanced age
($60 years) is associated with a low disease event rate
(19). Thus, in the present study, we longitudinally
tracked the impact of major treatment initiatives on
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1923the clinical course of adult patients between 30 and
59 years of age, with the rationale that the “midlife”
age group is most often encountered for diagnosis or
evaluation in clinical practice, as well as at-risk for
adverse disease-related events, including SD and
heart failure progression (1–3,5,9,12,15,16,31). We
elected not to incorporate younger HCM patients
in this report, who are encountered much less
frequently in practice, and often with early onset
aggressive disease expression (1–3,5,6,33–35).
Using our investigative strategy, we believe that the
expectation for longevity is favorably altered for many
HCM patients presenting in midlife, with a low mor-
tality rate directly attributable to utilization of
contemporary cardiovascular treatment options
(Central Illustration). It was not possible, however, to
assemble an untreated and rigidly matched controlgroup to address the improvedHCMmortality reported
here. Nevertheless, it is a reasonable assertion that, in a
cohort analysis such as ours, it is highly unlikely that
patients would have survived to the present without
treatment interventions known to preserve life, such
as ICDs, surgical myectomy, heart transplantation,
modern external deﬁbrillation techniques (and thera-
peutic hypothermia), or prevention of embolic stroke
death with prophylactic anticoagulant drugs.
For example, the HCM mortality rate among our
1,000 patients was just 0.5%/year, approximately 10-
fold lower than the 3% to 6%/year reported from ter-
tiary referral cohorts in a much earlier era, inﬂuenced
by highly skewed patient referral patterns (34–39). Our
HCM mortality rate documented here was also 3-fold
less than the 1.5% annual HCM-related rate of death
attached to this disease in the pre-ICD era (39).
TABLE 3 Univariate and Multivariate Predictors of HCM-Related Mortality or Life-Threatening Event
Parameter
Univariate Multivariate
HCM Death
or Event
(n ¼ 96)
No HCM Death
or Event
(n ¼ 904) Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
Age at diagnosis, yrs 34.8  12.2 41.0  11.0 0.963 (0.947–0.980) <0.001 0.967 (0.951–0.983) <0.001
Age of ﬁrst evaluation, yrs 43.8  8.2 45.9  8.5 0.986 (0.962–1.009) 0.24
Males 58 (60.4) 645 (71.4) 0.587 (0.389–0.886) 0.011 0.611 (0.400–0.933) 0.023
LVOT gradient $30 mm Hg at rest 27 (28.1) 245 (27.1) 1.084 (0.694–1.693) 0.72
Left atrial dimension, mm 46.0  9.8 41.9  6.7 1.064 (1.040–1.090) <0.001 1.048 (1.048–1.024) <0.001
LVED transverse dimension, mm 45.2  6.7 43.7  6.8 1.025 (0.993–1.058) 0.13
Maximal LV thickness, mm 23.1  6.8 21.6  5.3 1.033 (0.999–1.067) 0.057
Atrial ﬁbrillation 46 (47.9) 219 (24.2) 1.931 (1.291–2.892) 0.001
Presence of LGE* 21/25 (84.0) 179/440 (40.7) 5.250 (1.793–15.367) <0.001
NYHA functional class at study entry
I 39 (40.6) 487 (53.9)
II 27 (28.1) 248 (27.4) 1.544 (0.939–2.539) <0.001
III/IV 30 (31.3) 169 (18.7) 2.601 (1.606–4.211)
NYHA functional class at most recent evaluation
I 48 (20.0) 576 (65.2)
II 24 (25.0) 239 (27.1) 1.119 (0.683–1.834) <0.001 2.488 (1.514, 4.088)† 0.001
III/IV 24 (25.0) 68 (7.7) 3.457 (2.116–5.647)
Values are mean  SD or n (%). *n ¼ 465 patients; this variable was excluded from multivariate analysis. †NYHA functional class I was used as a reference at respective time points.
Abbreviations as in Table 1.
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1924The older mortality estimates contributed to the char-
acterization of HCM as an untreatable disease with a
uniformly grim prognosis, a view that has unfortu-
nately persisted, in part, to the present (10,20,40).
The relatively low HCM mortality rate of 0.5%/year
reported here is largely attributable to aborted and
nonfatal events, by virtue of utilizing the ICD for pri-
mary prevention of SD, as well as heart transplantation
for prevention of heart failure-related death (Central
Illustration). Indeed, when fatal and nonfatal HCM
events were combined, the overall HCM event rate
exceeded that in the general population, underscoring
the survival advantage provided by major and
contemporary therapeutic interventions translated to
HCM here. Furthermore, our HCM mortality did not
differ signiﬁcantly from that expected in the general
population, or that previously reported in HCM pa-
tients presenting $60 years of age (19). This revised
perception of HCM-related mortality can serve as a
measure of reassurance to many HCM patients, and
evidence of what is possible in this disease with
contemporary treatment.
Close inspection of clinical proﬁles in patients with
HCM-related death showed that many of the SDs that
occurred would be potentially preventable by current
practice standards (1–7,10). For example, several pa-
tients declined the ICD, even after receiving a stan-
dard formal recommendation for prophylactic device
therapy (1–3,5–7,12–15). Other patients were ﬁrstevaluated in the 1990s, an era preceding penetration
of ICDs into clinical practice for HCM and the avail-
ability of data supporting the efﬁcacy of device ther-
apy in this disease (15), or the expanded risk
stratiﬁcation models currently in use (1–3,5,6,16,27).
Should these patients be hypothetically considered as
likely survivors (with ICDs), the HCM-related mor-
tality rate would decrease to 0.4%/year.
Notably, 95% of our patients with appropriate ICD
interventions for VT/VF have survived to date, with
the vast majority experiencing favorable quality of
life with no or mild symptoms. Also, at the most
recent follow-up, 80% of heart transplant patients
had survived, representing a signiﬁcant extension in
life expectancy (17).
Our data support the evidence-based risk stratiﬁ-
cation strategy currently in widespread practice by
most HCM investigators and clinicians (1–3,5–7,10–15)
and in turn are supported by American College of
Cardiology/American Heart Association consensus
guidelines (5,6). Individual HCM patients can become
ICD candidates on the basis of 1 or more major SD risk
factors in their clinical proﬁle. This strategy has
proved effective in identifying most high-risk HCM
patients for prophylactic ICD implantation and SD
prevention (1–3,11–15), although different from that
used in coronary artery disease (41,42) or the complex
statistical/mathematical formula recently advanced
in HCM by O’Mahony et al. (8) for the European
FIGURE 3 Survival in Midlife HCM Adults
1.0
0.8
0.6
0.4
0.2
0.0
SMR: 1.68 (1.35, 2.08)
Log-rank test: p<0.001
All-Cause Mortality in HCM Patients (95% CI)(1.16%/year)
U.S. Expected Survival
Pr
op
or
tio
n 
of
 H
CM
 P
at
ie
nt
s S
ur
vi
vi
ng
0 5 10 15 20
Years From First Evaluation
A
1.0
0.8
0.6
0.4
0.2
0.0
SMR: 0.83 (0.61, 1.14)
Log-rank test: p=0.25
U.S. Expected Survival
Pr
op
or
tio
n 
of
 H
CM
 P
at
ie
nt
s S
ur
vi
vi
ng
0 5 10 15 20
Years From First Evaluation
HCM-Related Mortality (95% CI)(0.53%/year)
B
1.0
0.8
0.6
0.4
0.2
0.0
SMR: 2.11 (1.73, 2.58)
Log-rank test: p<0.001
U.S. Expected Survival
Pr
op
or
tio
n 
of
 H
CM
 P
at
ie
nt
s S
ur
vi
vi
ng
0 5 10 15 20
Years From First Evaluation
Combined HCM-Related Mortality and Aborted
Life-Threatening Events (95% CI)(1.36%/year)
C
Kaplan-Meier survival curves in 1,000 HCM patients, with relevant comparisons between subgroups and to expected all-cause mortality in the U.S. general population,
matched for age and sex. Dotted lines represent 95% conﬁdence intervals for survival probability. (A) All-cause mortality in HCM patients versus general population. (B)
HCM-related mortality versus all-cause mortality in the general population. (C) Combined life-threatening HCM events aborted by treatment interventions and HCM-
related mortality versus all-cause mortality in the general population. HCM ¼ hypertrophic cardiomyopathy.
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1925Society of Cardiology Guidelines (43). However,
the fact that some patients in our cohort study
experienced SD without conventional risk factors
(1–3,6,28,29) suggests the need for additional markers
in HCM, such as extensive LGE with quantitativecontrast CMR (24), which creates additional candi-
dates for ICDs and potentially results in even lower
HCM-related mortality.
In this study, 37 patients prospectively identiﬁed
as high-risk ultimately experienced potentially lethal
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: With
appropriate management, adult patients with HCM can
generally enjoy longevity comparable to age-matched
and sex-matched individuals in the general population.
COMPETENCY IN INTERPERSONAL AND
COMMUNICATION SKILLS: Physicians should
discuss with patients with HCM the array of contem-
porary management options available and offer reas-
surance (when appropriate) that with such therapy
they can aspire to normal or nearly normal longevity
and good quality of life.
TRANSLATIONAL OUTLOOK: Continued research
is needed to identify with greater precision patients
with HCM who beneﬁt from speciﬁc therapeutic
modalities, and to deﬁne the optimal timing for
various interventions.
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1926ventricular tachyarrhythmias that were terminated
by the ICD, dispelling the myth that risk markers
in HCM are relatively poor predictors (20,40). Never-
theless, the number of ICDs required to generate 1
implant that eventually intervened appropriately was
approximately 9:1, similar to that in randomized trials
of high-risk and clinically compromised patients
with coronary artery disease (41,42) or nonischemic
cardiomyopathy (44). However, because the arrhyth-
mogenic substrate in HCM has proven unpredictable
(1–3,10–15) and many at-risk patients are identiﬁed at
young ages (5,6,12,33,45), the present cross-sectional
study design does not exclude the possibility that
additional appropriate ICD interventions will continue
to occur in this cohort over time.
A substantial proportion of our patients died of
advanced heart failure or underwent heart trans-
plantation, suggesting that the epidemiology of HCM-
related mortality may be evolving to a new paradigm
in which end-stage heart failure (and its treatment) is a
more major component of the disease spectrum than
previously considered (16). It is even possible that
progressive advanced heart failure could soon replace
arrhythmic SD as the predominant cause of demise in
HCM (1,2,5,6,16–18). This shift may be explained, in
part, by SD prevention with ICDs or greater recogni-
tion of severe heart failure in HCMand its implications.
Over 5 decades, severe limiting drug-refractory
symptoms and progressive heart failure due to LV
outﬂow obstruction have been treated effectively by
surgical septal myectomy, resulting in reversal of
heart failure and greatly improved quality of life,
long-term survival equivalent to the general U.S.
population (31), and possible reduction in SD risk (46).
Performed with low operative risk (1,2,5,6,31,46,47),
90% of patients undergoing myectomy have survived
to end of follow-up (HCM-related death in <5%), with
improved quality of life attributable to abolition of
the outﬂow gradients responsible for heart failure
symptoms (1,2,31). Taken together, these observations
underscore the range of therapies effective in ex-
tending longevity (and improving quality of life) now
available to HCM patients.
STUDY LIMITATIONS. A large, well-deﬁned study
cohort, as presented here, permits detailed assessment
of the impact of major treatment interventions on the
clinical course of individual HCM patients. However,
assessing changes in mortality rates over time with
controlled comparisons between treated and untreated
patient groups in a heterogeneous and relatively un-
common disease, such as HCM is an impractical aspi-
ration. Finally, by demonstrating in principle what can
be achieved optimally in a focused HCM environment,
our data (although assembled from tertiary referralcenters) are relevant to more general and less highly
selected HCM patient populations (48,49).
CONCLUSIONS
This large, longitudinal, midlife cohort study un-
derscores the important principle that HCM has
evolved as a contemporary disease, now with the
potential to achieve a relatively low disease-related
mortality rate in the range of 0.5%/year. To this pur-
pose, we have used currently available major treat-
ment strategies and interventions in a large subset of
the HCM population (Central Illustration). Notably,
systematic utilization of the ICD to prevent SD has
altered the clinical disease course for many high-risk
HCM patients. As a consequence, the epidemiology
of HCM-related mortality is evolving, with advanced
heart failure emerging as a more major component of
the disease spectrum than previously regarded.
These data redeﬁne the mortality risk and alter the
historical perception of HCM as a relentless and pro-
gressive disease with limited effective treatment
options. In the process, we provide a measure of
reassurance to patients presenting in midlife, offering
many a reasonable aspiration for acceptable quality of
life and extended longevity.
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